Wednesday, 17 January 2018 07:50 GMT

Hekma Pharmaceuticals revenue up 41 percent in H1

(MENAFN) Hikma Pharmaceuticals announced posting a 44 percent increase in its profit in the January-June period due to a strong performance in its injectable business in the US, The Peninsula Qatar reported.

The Jordanian drug maker's revenue increased 41 percent, hitting USD346 million, while operating margins in the business was up 41 percent compared to 28.5 percent in the same period last year.

"This reflects exceptionally strong sales from certain market opportunities in the U.S., a focus on higher-value products and tight control of overhead costs across our manufacturing facilities," the company said.

  Most popular stories  

Day | Week | Month